Skip to main content

BioXcel Therapeutics, Inc.

BTAIQ
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001720893

No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.

Q3 2021 vs. Q2 2021

How the institutions holding BioXcel Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of BTAIQ: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders109104−5
Shares13.0M12.8M−238.4K (−1.8%)
Value$378.6M$388.3M+$9.62M (+2.5%)

New holders (12)

Institutions that held BioXcel Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to BTAIQ in Q3 2021
InstitutionSharesValue% of portfolio
Gsa Capital Partners LLP59,344$1.80M0.18%
Bailard, Inc.46,000$1.40M0.05%
Cubist Systematic Strategies, LLC19,087$579.0K0.01%
Marshall Wace, LLP12,488$379.0K0.00%
Susquehanna Fundamental Investments, LLC10,076$306.0K0.01%
Invesco Ltd.7,407$226.0K0.00%
SG Americas Securities, LLC6,822$207.0K0.00%
Point72 Hong Kong Ltd3,589$109.0K0.01%
Total Clarity Wealth Management, Inc.125$4.00K0.00%
Anchor Investment Management, LLC34$1.03K0.00%
Signaturefd, LLC40$1.00K0.00%
Berman Capital Advisors, LLC33$1.00K0.00%

Sold out (17)

Institutions that held BioXcel Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.